Kura Oncology Files 8-K

Ticker: KURA · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1422143

Kura Oncology, INC. 8-K Filing Summary
FieldDetail
CompanyKura Oncology, INC. (KURA)
Form Type8-K
Filed DateFeb 5, 2025
Risk Levellow
Pages6
Reading Time7 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, corporate-filing, financials

TL;DR

Kura Oncology filed an 8-K on Feb 5, 2025, reporting other events and financials.

AI Summary

Kura Oncology, Inc. filed an 8-K on February 5, 2025, reporting other events and financial statements. The company, incorporated in Delaware, is located at 12730 High Bluff Drive, Suite 400, San Diego, CA 92130, with a phone number of (858) 500-8800. This filing is a current report under the Securities Exchange Act of 1934.

Why It Matters

This 8-K filing indicates Kura Oncology is providing updates on its corporate activities and financial status to the SEC, which is important for investors to monitor.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain specific material events that would immediately impact risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Kura Oncology, Inc.?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of February 5, 2025.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on February 5, 2025.

What is Kura Oncology, Inc.'s principal executive office address?

Kura Oncology, Inc.'s principal executive office is located at 12730 High Bluff Drive, Suite 400, San Diego, CA 92130.

What is the telephone number for Kura Oncology, Inc.?

The telephone number for Kura Oncology, Inc. is (858) 500-8800.

Was Kura Oncology, Inc. previously known by another name?

Yes, Kura Oncology, Inc. was formerly known as ZETA ACQUISITION CORP III, with a date of name change on December 27, 2007.

Filing Stats: 1,734 words · 7 min read · ~6 pages · Grade level 15.6 · Accepted 2025-02-05 16:13:00

Key Financial Figures

Filing Documents

Forward-Looking Statements

Forward-Looking Statements Any forward-looking statements in this Current Report on Form 8-K are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that the Company may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, applications and other interactions with regulatory bodies, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializin

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Presentation Materials of Kura Oncology, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KURA ONCOLOGY, INC. Date: February 5, 2025 By: /s/ Teresa Bair Teresa Bair Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing